Canadian HR Strategy

Spring/Summer 2016

Human Resources Issues for Senior Management

Issue link:

Contents of this Issue


Page 6 of 31

CANADIAN HR STRATEGY/07 FEATURE/roundtable "That's phenomenal from a drug treatment perspective. It's had an unanticipated effect on those who are paying for the programs in that now you're treating something for many years as a chronic disease in a very expensive manner in some cases and differently than you would have in the past," he says. "That's created a timeline of how long someone will be on a very expensive therapy that's different now than it was 10 years ago. It really ows through into something like large-amount pooling, which has become a huge challenge for many orga- nizations, whether you're talking about the insurance industry or about employers. You're now funding treatment for chronic diseases that can be upwards of $30,000 or $50,000 or $500,000 a year." DISEASES THAT USED TO BE DEATH SENTENCES ARE CHRONIC DISEASES.

Articles in this issue

Archives of this issue

view archives of Canadian HR Strategy - Spring/Summer 2016